Jailendra Singh
Stock Analyst at Truist Securities
(0.79)
# 4,049
Out of 5,132 analysts
186
Total ratings
24.27%
Success rate
-27.73%
Average return
Main Sectors:
Stocks Rated by Jailendra Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Hold | $555 → $539 | $428.03 | +25.93% | 7 | Feb 11, 2026 | |
| DOCS Doximity | Maintains: Buy | $62 → $37 | $25.02 | +47.88% | 10 | Feb 6, 2026 | |
| MDLN Medline | Initiates: Buy | $52 | $44.55 | +16.72% | 1 | Jan 12, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $265 → $290 | $166.94 | +73.72% | 18 | Jan 8, 2026 | |
| ICLR ICON Public Limited Company | Downgrades: Hold | $231 → $222 | $93.00 | +138.71% | 11 | Jan 8, 2026 | |
| FTRE Fortrea Holdings | Upgrades: Buy | $12 → $22 | $9.79 | +124.72% | 1 | Jan 8, 2026 | |
| PRVA Privia Health Group | Reiterates: Buy | $30 → $31 | $22.39 | +38.45% | 8 | Nov 10, 2025 | |
| EVH Evolent Health | Maintains: Buy | $16 → $10 | $2.79 | +258.42% | 8 | Nov 10, 2025 | |
| PHR Phreesia | Maintains: Buy | $35 → $36 | $11.95 | +201.26% | 7 | Sep 8, 2025 | |
| HIMS Hims & Hers Health | Maintains: Hold | $48 → $37 | $16.30 | +126.99% | 11 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $51 | $22.41 | +127.58% | 3 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $24 → $27 | $20.69 | +30.50% | 10 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $38.94 | +23.27% | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $10 → $9 | $4.65 | +93.55% | 16 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.5 → $5.5 | $2.18 | +152.29% | 12 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $12 → $7.5 | $5.40 | +38.89% | 7 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $46 | $18.78 | +144.94% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $261 → $210 | $174.11 | +20.61% | 7 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $14 | $12.75 | +9.80% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.4 → $6.5 | $0.36 | +1,700.55% | 8 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $13 | $1.70 | +664.71% | 11 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $24 | $1.59 | +1,409.43% | 2 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $4 | $0.89 | +347.03% | 4 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $58 | $220.79 | -73.73% | 2 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $90 → $45 | $1.80 | +2,400.00% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $230 → $333 | $934.75 | -64.38% | 6 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $9 | $2.02 | +345.54% | 2 | May 19, 2021 |
Medpace Holdings
Feb 11, 2026
Maintains: Hold
Price Target: $555 → $539
Current: $428.03
Upside: +25.93%
Doximity
Feb 6, 2026
Maintains: Buy
Price Target: $62 → $37
Current: $25.02
Upside: +47.88%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $52
Current: $44.55
Upside: +16.72%
IQVIA Holdings
Jan 8, 2026
Maintains: Buy
Price Target: $265 → $290
Current: $166.94
Upside: +73.72%
ICON Public Limited Company
Jan 8, 2026
Downgrades: Hold
Price Target: $231 → $222
Current: $93.00
Upside: +138.71%
Fortrea Holdings
Jan 8, 2026
Upgrades: Buy
Price Target: $12 → $22
Current: $9.79
Upside: +124.72%
Privia Health Group
Nov 10, 2025
Reiterates: Buy
Price Target: $30 → $31
Current: $22.39
Upside: +38.45%
Evolent Health
Nov 10, 2025
Maintains: Buy
Price Target: $16 → $10
Current: $2.79
Upside: +258.42%
Phreesia
Sep 8, 2025
Maintains: Buy
Price Target: $35 → $36
Current: $11.95
Upside: +201.26%
Hims & Hers Health
Aug 18, 2025
Maintains: Hold
Price Target: $48 → $37
Current: $16.30
Upside: +126.99%
Jul 17, 2025
Maintains: Buy
Price Target: $50 → $51
Current: $22.41
Upside: +127.58%
Jul 17, 2025
Maintains: Hold
Price Target: $24 → $27
Current: $20.69
Upside: +30.50%
Jun 16, 2025
Initiates: Buy
Price Target: $48
Current: $38.94
Upside: +23.27%
May 27, 2025
Maintains: Hold
Price Target: $10 → $9
Current: $4.65
Upside: +93.55%
Apr 10, 2025
Maintains: Hold
Price Target: $6.5 → $5.5
Current: $2.18
Upside: +152.29%
Apr 10, 2025
Maintains: Hold
Price Target: $12 → $7.5
Current: $5.40
Upside: +38.89%
Mar 18, 2025
Maintains: Buy
Price Target: $50 → $46
Current: $18.78
Upside: +144.94%
Jan 13, 2025
Maintains: Hold
Price Target: $261 → $210
Current: $174.11
Upside: +20.61%
Jul 2, 2024
Maintains: Buy
Price Target: $17 → $14
Current: $12.75
Upside: +9.80%
May 24, 2024
Maintains: Hold
Price Target: $6.4 → $6.5
Current: $0.36
Upside: +1,700.55%
May 4, 2022
Maintains: Neutral
Price Target: $16 → $13
Current: $1.70
Upside: +664.71%
Feb 24, 2022
Maintains: Neutral
Price Target: $30 → $24
Current: $1.59
Upside: +1,409.43%
Feb 8, 2022
Downgrades: Neutral
Price Target: $14 → $4
Current: $0.89
Upside: +347.03%
Feb 4, 2022
Maintains: Neutral
Price Target: $60 → $58
Current: $220.79
Upside: -73.73%
Jan 7, 2022
Downgrades: Underperform
Price Target: $90 → $45
Current: $1.80
Upside: +2,400.00%
Jan 7, 2022
Upgrades: Outperform
Price Target: $230 → $333
Current: $934.75
Upside: -64.38%
May 19, 2021
Maintains: Neutral
Price Target: $10 → $9
Current: $2.02
Upside: +345.54%